DiaMedica Therapeutics Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________ Commission File Number: 001-36291 DIAMEDICA THERAPEUTICS INC.(Exact name of registrant as specified in its charter) British Columbia, Canada(State or other jurisdiction of incorporation or organization)Not Applicable(I.R.S. Employer Identification No.) 301 Carlson Parkway, Suite 210Minneapolis, Minnesota 55305(Address of principal executive offices) (Zip Code) (763) 496-5454(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ As of May 4, 2026, there were 53,883,345 voting common shares of the registrant outstanding. DiaMedica Therapeutics Inc.FORM 10-QMarch 31, 2026 TABLE OF CONTENTS Description Page This quarterly report on Form 10-Q contains certain forward-looking statements that are within the meaning of Section 27A of theUnited States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended,and are subject to the safe harbor created by those sections. For more information, see“Cautionary Note Regarding Forward-LookingStatements.” As used in this report, references to“DiaMedica,”the“Company,”“we,”“our”or“us,”unless the context otherwise requires, refer toDiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica’s condensed consolidated financialstatements. References in this report to“common shares”mean our voting common shares, no par value per share. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks andtrade names in this report are referred to without the®and™symbols, but such references should not be construed as any indicatorthat the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We donot intend the use or display of other companies’trademarks and trade names to imply a relationship with, or endorsement orsponsorship of us by, any other companies. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements in this report that are not descriptions of historical facts are forward-looking statements within the meaning of the UnitedStates Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations and are subject to risksand uncertainties that could negatively affect our business, operating results, financial condition, prospects and share price. We haveattempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,”“estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” “will,” “would,” the negative of these terms orother comparable terminology and the use of future dates. The forward-looking statements in this report are subject to risks and uncertainties and include, among other things: ●our plans to develop, obtain U.S. Food and Drug Administration approval for the clinical study of DM199 for preeclampsia(PE) and fetal growth restriction (FGR) and ultimately to obtain regulatory approval for and commercialize our DM199product candidate for the treatment of PE,